Testosterone enanthate

Use extreme caution, as testosterone enanthate is associated with an increased risk of elevated BP, which may lead to major adverse cardiovascular events, particularly in patients with cardiovascular risk or pre-existing hypertension. Before starting treatment, assess baseline cardiovascular risk, ensure BP control, and monitor BP 6 weeks after initiation and periodically thereafter. Manage new-onset or worsening hypertension and re-evaluate therapy risks versus benefits in patients who develop cardiovascular risk factors or disease.

Use caution in patients on prolonged high doses of testosterone enanthate.

Maintain a high level of suspicion, as testosterone enanthate therapy may decrease TBG concentrations.

Use caution in patients on large doses of testosterone enanthate, as it may suppress spermatogenesis and reduce sperm count.

Use caution with testosterone enanthate outside approved dosages or indications, as abuse may lead to dependence, addiction, and withdrawal symptoms.

Use caution in patients with depression.

Maintain a high level of suspicion, as testosterone enanthate is often abused at higher-than-recommended doses and in combination with other anabolic steroids, leading to serious cardiovascular and psychiatric adverse effects. Counsel patients on these risks. If abuse is suspected, check serum testosterone levels, noting they may appear normal or subnormal in men using synthetic derivatives, and consider abuse in patients with severe cardiovascular or psychiatric symptoms.

Maintain a high level of suspicion, as testosterone enanthate is associated with a risk of dyslipidemia. Periodically monitor the lipid profile, particularly at the start of therapy.

Maintain a high level of suspicion, as testosterone enanthate has been associated with an increased risk of polycythemia/erythrocytosis, typically observed within 1 month to 1 year after initiation. Evaluate hematocrit before starting therapy, reassess at 3 to 6 months, and monitor annually. Discontinue if hematocrit exceeds 54%.

Use caution in patients with BPH.

Use caution in patients with pre-existing cardiac, renal, or hepatic disease.

Maintain a high level of suspicion, as testosterone enanthate is associated with an increased risk of gynecomastia, which may be persistent.

Use caution in patients with cancer or prolonged immobilization.

Maintain a high level of suspicion, as studies suggest a potential risk of major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, with testosterone enanthate, though the evidence remains inconclusive.

Maintain a high level of suspicion, as testosterone enanthate is associated with an increased risk of prostatic carcinoma.

Use caution in obese patients or those with chronic lung disease.

Maintain a high level of suspicion, as testosterone enanthate is associated with an increased risk of DVT and PE. Discontinue therapy if VTE is suspected.